Evidence map›Paper›PMID 39603630›Full record

ArticleInternal medicine (Tokyo, Japan)2025

Idiopathic Multicentric Castleman Disease Diagnosed after Lower Extremity Venous Thrombosis Mimicking Immunoglobulin G4-related Disease.

Eiji Suzuki, Haruki Matsumoto, Shuhei Yoshida, Kenji Saito, Tomoyuki Asano, Hajime Odajima, Takashi Kanno, Kiyoshi Migita

Abstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Eiji SuzukiDepartment of Rheumatology, Ohta-Nishinouchi Hospital, Japan.
Haruki MatsumotoDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Shuhei YoshidaDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Kenji SaitoDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Tomoyuki AsanoDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.
Hajime OdajimaDepartment of Pathology, Ohta-Nishinouchi Hospital, Japan.
Takashi KannoDepartment of Rheumatology, Ohta-Nishinouchi Hospital, Japan.
Kiyoshi MigitaDepartment of Rheumatology, Fukushima Medical University School of Medicine, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

It is difficult to distinguish idiopathic multicentric Castleman disease (iMCD) from immunoglobulin G4-related disease (IgG4-RD). A 47-year-old man was diagnosed with venous thrombosis in the right lower extremity. Multiple lymphadenopathies and splenomegaly were incidentally detected. His serum IgG4 levels were high, and the biopsied lymph nodes showed high plasma cell infiltration with many IgG4-positive cells between the follicles. He was initially diagnosed with IgG4-RD and was administered prednisolone 30 mg/day; however, inflammation and IgG4 persisted. The patient was rediagnosed with iMCD and treated with tocilizumab, which led to an improvement of his condition. When diagnosing IgG4-RD, it is therefore important to consider iMCD in the differential diagnosis.

Indexed as

Castleman DiseaseImmunoglobulin GImmunoglobulin G4-Related DiseaseLower ExtremityVenous ThrombosisAntibodies, Monoclonal, HumanizedDiagnosis, DifferentialHumansMaleMiddle AgedAntibodies, Monoclonal, HumanizedImmunoglobulin Gtocilizumabglucocorticoididiopathic multicentric Castleman diseaseimmunoglobulin G4-related diseasetocilizumabvenous thrombosis

Identifiers

PMID39603630
PMCPMC12241779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.